Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1900 - A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Yu Sunakawa

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

Y. Sunakawa1, S. Stintzing2, S. Cao3, J. Luecke4, D. Thompson4, M. Moran5, S.H. Astrow6, J. Hsiang5, C. Stephens5, W. Zhang7, A. Tsuji8, T. Takahashi9, T. Denda10, K. Shimada11, M. Kochi12, M. Takeuchi13, M. Fujii14, W. Ichikawa9, V. Heinemann15, H.J. Lenz7

Author affiliations

  • 1 Clinical Oncology, St. Marianna University School of Medicine, 216-8511 - Kawasaki/JP
  • 2 Medical Oncology, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 3 Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 4 Biostatistics And Bioinformatics, HTG Molecular Diagnostics Inc., 85706 - Tucson/US
  • 5 R&d And Pharmaceutical Services, Cancer Genetics, Inc., 90033 - Los Angeles/US
  • 6 Na, Kite, a Gilead Company, 90404 - Santa Monica/US
  • 7 Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 8 Clinical Oncology, Kagawa University Hospital, 7610793 - Kagawa/JP
  • 9 Medical Oncology, Showa University Fujigaoka Hospital, 2278501 - Yokohama/JP
  • 10 Gastroenterology, Chiba Cancer Center, 260-8717 - Chiba/JP
  • 11 Medical Oncology, Showa University Koto Toyosu Hospital, 135-8577 - Tokyo/JP
  • 12 Digestive Surgery, Nihon University School of Medicine, 1738610 - Tokyo/JP
  • 13 Clinical Medicine (biostatistics), Kitasato University, tokyo/JP
  • 14 Digestive Surgery, Nihon University School of Medicine, 173-8610 - Tokyo/JP
  • 15  department Of Medical Oncology And Comprehensive Cancer Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
More

Resources

Abstract 1900

Background

We conducted a biomarker study to identify significant genes to predict efficacy of cetuximab (cet) based treatment using tumor samples from mCRC patients (pts) enrolled in JACCRO CC-05/06AR (UMIN000010635) and FIRE-3 (NCT00433927), which evaluated 1st-line doublet plus cet therapy. There are no established predictive biomarkers beyond RAS mutations. We reported recently CDX2 gene expression levels as a promising biomarker for cet treatment in KRAS wild-type mCRC pts of the JACCRO trial (ASCO 2016, abst3592). Therefore, we performed the validation study using tumor samples from pts enrolled in the FIRE-3 trial.

Methods

We analyzed tissue samples of 77 pts of the JACCRO trial for discovery set and 250 pts of cet arm in the FIRE-3 trial for validation set. Gene expression levels were measured by HTG EdgeSeq Oncology Biomarker Panel, which is comprised of probes targeting 2560 genes implicated in numbers of pathways, using next generation sequencing for quantitative analysis of targeted RNAs. Univariate Cox regression analysis was conducted for all genes that passed QC filtering.

Results

Seventy-one pts (male/female, 39/32; median age, 63 yrs) and 102 pts (male/female, 75/27; median age, 63 yrs) were successful for gene expression analysis in the JACCRO and FIRE-3 set, respectively. The Cox regression analysis identified 24 genes for overall survival (OS) and 8 genes for progression-free survival (PFS), which all were significant (p < 0.005) in the JACCRO set. Among those genes, LYZ and RNF43 genes were found to be significantly associated with OS (coefficients, 0.21; p = 0.013) and PFS (coefficients, -0.20; p = 0.037), respectively, in the FIRE-3 set. In the JACCRO set, high expression (log2>9.07) of CDX2 predicted a significantly longer PFS (p = 0.002). The same effect was found in the FIRE-3 set when applied the same cutoff value (median PFS 10.9 vs. 6.9 months, HR 0.39, 95%CI 0.22-0.72, p = 0.002).

Conclusions

Our biomarker study validated CDX2 as a novel predictor for clinical outcome of 1st-line cet based chemotherapy in mCRC. These data warrant further exploration of CDX2 as a biomarker or as a potential target for drug development.

Clinical trial identification

UMIN000010635.

Legal entity responsible for the study

Heinz-Josef Lenz.

Funding

JACCRO, the National Cancer Institute (grant number P30CA014089), The Gloria Borges WunderGlo Foundation-The Wunder Project, Dhont Family Foundation, San Pedro Peninsula Cancer Guild, and Daniel Butler Research Fund.

Editorial Acknowledgement

We acknowledge Sachika Koyama and Yasushi Ohtake (JACCRO) for editorial assistance.

Disclosure

Y. Sunakawa: Honoraria for talks: Taiho Pharmaceutical, Chugai Pharma, Yakult Honsha, Takeda, Merck Serono, Bayer Yakuhin, Sanofi. S. Stintzing: Consulting or advisory role, travel expenses, honoraria: Merck KGaA. A. Tsuji: Honoraria: Taiho Pharmaceutical, Merck Serono. T. Denda: Honoraria: Yakult Honsha, Taiho Pharmaceutical. K. Shimada: Corporate-sponsored research fee: Yakult Honsha, Taiho Pharmaceutical. M. Takeuchi: Consulting fees: Hisamitsu Pharmaceutical, Kowa, Shionogi Pharma, Abbvie, Astellas. W. Ichikawa: Consulting fees: Ono Pharmaceutical; Research funding: Takeda, Taiho Pharmaceutical, Eisai, Chugai Pharma, Merck Serono, Shionogi Pharma, Daiichi Sankyo; Honoraria: Merck Serono, Taiho Pharmaceutical, Chugai Pharma, Takeda, Ono Pharmaceutical, Lilly. V. Heinemann: Consulting or advisory role, travel expenses, honoraria, research funding: Merck. H-J. Lenz: Consulting or advisory role, travel expenses, honoraria, Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings